➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Boehringer Ingelheim
Baxter
Merck
Medtronic

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

Ertugliflozin - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for ertugliflozin and what is the scope of patent protection?

Ertugliflozin is the generic ingredient in three branded drugs marketed by Merck Sharp Dohme and is included in three NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ertugliflozin has fifty-nine patent family members in forty-eight countries.

One supplier is listed for this compound.

Summary for ertugliflozin
International Patents:59
US Patents:6
Tradenames:3
Applicants:1
NDAs:3
Suppliers / Packagers: 1
Bulk Api Vendors: 47
Clinical Trials: 32
Patent Applications: 47
DailyMed Link:ertugliflozin at DailyMed
Recent Clinical Trials for ertugliflozin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yonsei UniversityPhase 3
Yale UniversityPhase 2
Asan Medical CenterPhase 3

See all ertugliflozin clinical trials

US Patents and Regulatory Information for ertugliflozin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme SEGLUROMET ertugliflozin; metformin hydrochloride TABLET;ORAL 209806-004 Dec 19, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Merck Sharp Dohme STEGLUJAN ertugliflozin; sitagliptin phosphate TABLET;ORAL 209805-001 Dec 19, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Merck Sharp Dohme SEGLUROMET ertugliflozin; metformin hydrochloride TABLET;ORAL 209806-001 Dec 19, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ertugliflozin

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2334687 132018000000441 Italy   Start Trial PRODUCT NAME: ERTUGLIFLOZIN(STEGLATRO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1267, 20180323
2334687 1890026-6 Sweden   Start Trial PRODUCT NAME: ERTUGLIFLOZIN,OPTIONALLY IN THE FORM OF ERTUGLIFOZIN L- PYROGLUTAMIC ACID; REG. NO/DATE: EU/1/18/1267 20180323
2334687 C02334687/01 Switzerland   Start Trial PRODUCT NAME: ERTUGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 66577 18.10.2018
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKinsey
Harvard Business School
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.